|
Alan Sandler is a Professor of Medicine in the Division of Hematology & Medical Oncology, Department of Medicine, at Oregon Health & Science University in Portland, Oregon and is the DeArmond Chair for Clinical Cancer Research. After earning a B.S. in Pharmacy (cum laude) at the University of Toledo in Ohio and an M.D. at Rush Medical College in Chicago, Dr. Sandler completed an internship and residency in Internal Medicine at Yale-New Haven Hospital and a Fellowship in Medical Oncology at the Yale University School of Medicine in New Haven, Connecticut. His academic honors include membership in Alpha Omega Alpha and Rho Chi, the medical and pharmaceutical honor societies. Dr. Sandler is a member of the American Society of Clinical Oncology, and the Eastern Cooperative Oncology Group, where he serves as the Co-Chair of the Thoracic Committee. He is principal investigator or co-principal investigator of several therapeutic clinical trials that evaluate the activity of chemotherapeutic agents and/or combined-modality therapies in both small and non-small cell lung cancer as well as sarcoma. Dr. Sandler serves on the Editorial Boards of Clinical Lung Cancer and the Japanese Journal of Clinical Oncology, and is a reviewer for several journals including The New England Journal of Medicine, Journal of Clinical Oncology, Cancer Investigations, Cancer, the British Journal of Cancer, and European Respiratory Journal. Dr. Sandler is the author or co-author of more than 200 published articles, book chapters, reviews, and abstracts involving the pharmacology and clinical activity of chemotherapy and novel targeted agents, with a particular emphasis on lung cancer. Dr. Alan Sandler, Oregon Health & Science University–Knight Cancer Institute from TEAM DRAFT on Vimeo. |
Awareness • Early Detection • Treatment • Research • Survivorship